AUA/SUO非肌层浸润性膀胱癌风险分组在当代队列中的使用与验证
该研究回顾性分析了2001至2017年398例非肌层浸润性膀胱癌患者,应用AUA/SUO指南进行风险分层,并分析复发和进展的预测因素。结果显示低、中、高危组的5年进展无生存率分别为93%、74%和54%,5年无复发生存率分别为43%、33%和23%,风险分组是进展和复发的独立预测因素。
要点
- AUA/SUO风险分组可有效区分非肌层浸润性膀胱癌的复发和进展风险。
- 高危组较低危组的进展风险显著增高(HR 36)。
- 建议在诊断时使用该分组进行患者咨询和治疗指导。
核心结论
- AUA/SUO非肌层浸润性膀胱癌风险分类系统能根据复发和进展可能性适当分层患者,应在诊断时用于咨询和指导治疗。
研究设计与样本
- 回顾性队列研究,纳入2001至2017年398例非肌层浸润性膀胱癌患者,中位随访37个月(95%CI 35-42)。
主要发现
- 低、中、高危组分别占11.5%、32.5%、55.8%。
- 低、中、高危组5年进展无生存率分别为93%、74%、54%,5年无复发生存率分别为43%、33%、23%。
- 中危和高危相对于低危的进展风险HR分别为9.7(95%CI 2.23-42.0,p<0.01)和36(95%CI 8.16-159,p<0.001)。
- 高危组复发风险较低危组增高(HR 2.03,95%CI 1.11-3.71,p=0.022)。
- 复发和进展的1年AUC分别为0.60(95%CI 0.546-0.656)和0.68(95%CI 0.622-0.732)。
临床怎么用
- 在诊断时应用AUA/SUO风险分组对患者进行风险分层,以辅助临床决策和患者咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We applied nonmuscle invasive bladder cancer AUA (American Urological Association)/SUO (Society of Urologic Oncology) guidelines for risk stratification and analyzed predictors of recurrence and progression. MATERIALS AND METHODS: We retrospectively reviewed the records of 398 patients with nonmuscle invasive bladder cancer treated between 2001 and 2017. Descriptive statistics were used to compare AUA/SUO risk groups. Predictors of recurrence and progression were determined by multivariable regression. Kaplan-Meier analysis was done, a Cox proportional hazards regression model was created and time dependent AUCs were calculated to determine progression-free and recurrence-free survival by risk group. RESULTS: Median followup was 37 months (95% CI 35-42). Of the patients 92% underwent bacillus Calmette-Guérin induction and 46% received at least 1 course of maintenance treatment. Of the patients 11.5% were at low, 32.5% were at intermediate and 55.8% were at high risk. In patients at low, intermediate and high risk the 5-year progression-free survival rate was 93%, 74% and 54%, and the 5-year recurrence-free survival rate was 43%, 33% and 23%, respectively. Kaplan-Meier analysis was done to stratify high grade Ta 3 cm or less tumor recurrence-free and progression-free survival in the intermediate vs the high risk group. Relative to low risk, classification as intermediate and as high risk was an independent predictor of progression (HR 9.7, 95% CI 2.23-42.0, p <0.01, and HR 36, 95% CI 8.16-159, p <0.001, respectively). Recurrence was more likely in patients at high risk than in those at low risk (HR 2.03, 95% CI 1.11-3.71, p=0.022). For recurrence and progression the 1-year AUC was 0.60 (95% CI 0.546-0.656) and 0.68 (95% CI 0.622-0.732), respectively. CONCLUSIONS: The AUA/SUO nonmuscle invasive bladder cancer risk classification system appropriately stratifies patients based on the likelihood of recurrence and progression. It should be used at diagnosis to counsel patients and guide therapy.
引用
- Ritch CR, Velasquez MC, Kwon D, et al. Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort. J Urol. 2019. PMID: 31609178. doi:10.1097/JU.0000000000000593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。